In December 2021, the European Association for the Study of the Liver (EASL)–Lancet Commission on liver disease in Europe launched its first report, which highlighted an alarming increase in liver-related mortality in many European countries. The Commission proposed a roadmap for addressing the documented negative trends. However, quoting one of the accompanying Comment articles, “gaining consensus […]
Summary In 2014, an analysis was conducted to evaluate the hepatitis C virus (HCV) epidemiology and disease burden in Germany. Since then, there have been considerable developments in HCV management such as the implementation of direct acting antivirals. The aim of this analysis was to assess the recent data available for Germany, establish an updated […]
Summary The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis […]
Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modeling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, […]
Summary Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic